Racial And Ethnic Diversity In Clinical Trials: A Social And Scientific Imperative
From new FDA guidance and community engagement efforts to the challenges of precision medicine and decentralization, In Vivo spoke with industry experts about racial and ethnic diversity in the context of clinical trials.
You may also be interested in...
No negative actions have been taken in the US FDA’s oncology review divisions, but vague diversity guidance continues to raise concerns.
Catherine Gregor is the chief clinical trial officer at Florence Healthcare, a leading provider of clinical trial software that helps researchers collaborate and manage workflows and information. Based on her extensive experience in clinical research administration, Gregor explains how the recent US FDA guidance on diversity and inclusion in clinical trials represents a critical opportunity to make clinical research more inclusive and equitable.
The FDA commissioner says that improving health disparities would fix the lack of diversity in clinical trials.